ReBEC Clinical Trial Registry Analysis: Brazil's 2020-2024 Trial Demographics & Therapeutics
Decision brief
Answer first · skim in under a minute
This article delves into the ReBEC Clinical Trial Registry, analyzing Brazil's trial demographics and therapeutics from 2020 to 2024, highlighting key drug developments.
Key questions this brief answers
- What is the ReBEC Clinical Trial Registry and why is it important?
- What is Brazil's clinical trials market size and growth forecast?
- Which therapeutic areas dominate Brazil's clinical trials?
- How does Brazil compare to other Latin American clinical trial markets?
- What regulatory changes are affecting Brazil's clinical trials?
Brazil's ReBEC Clinical Trial Registry currently holds 18,534 registered trials, reflecting the country's emergence as Latin America's largest clinical research hub. The Brazilian market reached USD 316.6 million in 2024 and is projected to grow at a 3.9% CAGR through 2032, driven by chronic disease prevalence, cost advantages over North America, and regulatory streamlining by ANVISA.
Contents11 sections
Key Takeaways
- ReBEC contains 18,534 registered trials as of 2024, with 5,123 actively recruiting, managed by Brazil's Ministry of Health, PAHO, and FIOCRUZ
- Brazil's clinical trials market is forecast to grow from USD 316.6M (2024) to USD 443.5M (2032) at 3.9% CAGR
- Top therapeutic areas: oncology, cardiovascular, infectious diseases, CNS disorders, and metabolic conditions
- New legislation effective August 2024 streamlines approvals and strengthens participant protections
- Brazil offers cost advantages and diverse patient populations, attracting global sponsors including IQVIA, ICON, and Charles River Laboratories
What Is ReBEC and How Does It Work?
ReBEC (Registro Brasileiro de Ensaios Clínicos) serves as Brazil's official clinical trial registry. The platform operates as a joint initiative between the Ministry of Health's DECIT, the Pan American Health Organization (OPAS/PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). ANVISA provides regulatory oversight.
The registry currently contains 18,534 trials in various stages: 9,414 fully registered, 5,123 actively recruiting participants, 106 under review, and 6,174 in draft status. Registration is mandatory before trial initiation in Brazil, as required by ANVISA regulations. The platform accelerates clinical research while prioritizing indigenous health and neglected tropical diseases.
How Large Is Brazil's Clinical Trials Market?
Brazil's clinical trials market reached USD 316.6 million in 2024. Industry forecasts project expansion to USD 443.5 million by 2032, representing a compound annual growth rate (CAGR) of 3.9%. This growth trajectory positions Brazil as the largest clinical research market in Latin America.
Several factors drive this expansion. Brazil offers cost-effectiveness compared to North American and European trial sites. The country's diverse population of approximately 215 million provides rich recruitment pools. Chronic disease prevalence—including 704,000 new cancer cases in 2023 per INCA (National Cancer Institute)—creates high demand for innovative therapeutics.
Which Therapeutic Areas Dominate ReBEC Registrations?
Analysis of ReBEC registry data reveals five predominant therapeutic areas driving clinical trial activity:
| Therapeutic Area | Key Focus Areas | Disease Burden Context |
|---|---|---|
| Oncology | Solid tumors, hematologic malignancies | 704,000 new cancer cases (2023) |
| Cardiovascular | Hypertension, heart failure | High prevalence of hypertension |
| Infectious Diseases | HIV, tropical diseases | Significant infectious disease burden |
| CNS Disorders | Neurodegenerative diseases | Growing aging population |
| Metabolic Disorders | Diabetes, obesity | Rising diabetes rates |
This distribution aligns directly with Brazil's disease burden epidemiology. Sponsors target therapeutic areas with high clinical need and regulatory incentive structures, optimizing approval likelihood in Brazil and broader Latin American markets. ClinicalTrials.gov data shows Brazil as a top recruitment location for international multi-center trials.
Who Are the Major Players in Brazil's Clinical Trials Sector?
The competitive landscape includes contract research organizations (CROs) and pharmaceutical companies. Key market players include IQVIA Inc., Laboratory Corporation of America Holdings, ICON plc, and Charles River Laboratories. Multinational pharmaceutical companies including Roche, Novartis, Pfizer, and Merck also maintain active trial portfolios in Brazil.
This sponsorship diversity indicates Brazil's attractiveness to both global and local research organizations. International sponsors increasingly establish clinical trial operations in Latin America, drawn by cost advantages and patient access.
What Regulatory Changes Are Shaping the Market?
ANVISA's regulatory framework continues evolving. New legislation effective August 2024 streamlines trial approval processes while strengthening participant protections. These changes address previous challenges including lengthy approval timelines.
Additional anticipated developments include expanded acceptance of real-world evidence, adaptive trial designs, and expedited pathways for breakthrough therapies. Digital health integration—including electronic health records, remote monitoring, and decentralized trial elements—is also expanding.
How Does Brazil Compare to Other Latin American Markets?
Brazil's ReBEC registry demonstrates higher trial volumes and more diverse therapeutic focus compared to other Latin American countries. The country's larger patient population, established regulatory infrastructure through ANVISA, and growing clinical research capacity distinguish it from regional competitors. Brazil also participates in international registries, with trials listed on ClinicalTrials.gov for global visibility.
Brazil's market size of USD 316.6 million in 2024 significantly exceeds other Latin American markets. The projected growth reinforces Brazil's position as the most active clinical trials market in the region, attracting both global pharmaceutical companies and emerging biotech firms seeking cost-effective trial sites.
What Challenges Does Brazil's Clinical Trials Market Face?
Several challenges persist despite growth opportunities. The regulatory framework involves multiple agencies, creating complexity for sponsors. Historical approval timelines reached 18 months, though recent reforms aim to reduce this.
Resource constraints also affect the market. Limited financial and human resources, combined with shortages of skilled workforce in specialized therapeutic areas, can impact trial execution. Post-COVID recovery has been gradual, with deferred studies resuming in 2021–2022 after pandemic-related postponements.
Frequently Asked Questions
What is the ReBEC Clinical Trial Registry and why is it important?
ReBEC (Registro Brasileiro de Ensaios Clínicos) is Brazil's official clinical trial registry managed by the Ministry of Health, Pan American Health Organization (OPAS), and FIOCRUZ, with ANVISA oversight. It currently holds 18,534 registered trials. The registry ensures transparency, regulatory compliance, and participant safety in clinical research. For pharmaceutical companies, ReBEC is mandatory for trial initiation and serves as a critical tool for understanding Brazil's clinical research landscape.
What is Brazil's clinical trials market size and growth forecast?
Brazil's clinical trials market reached USD 316.6 million in 2024 and is projected to grow to USD 443.5 million by 2032, representing a compound annual growth rate (CAGR) of 3.9%. Growth drivers include increased pharmaceutical investment in chronic disease therapeutics, cost-effectiveness compared to North America and Europe, and regulatory improvements streamlining approval processes.
Which therapeutic areas dominate Brazil's clinical trials?
The predominant therapeutic areas in ReBEC registry data are oncology, cardiovascular diseases, infectious diseases, central nervous system (CNS) disorders, and metabolic disorders. These areas align with Brazil's disease burden, including high prevalence of cancer (704,000 new cases in 2023), diabetes, hypertension, and infectious diseases.
How does Brazil compare to other Latin American clinical trial markets?
Brazil's ReBEC registry demonstrates higher trial volumes and more diverse therapeutic focus compared to other Latin American countries. With a population of approximately 215 million, established regulatory infrastructure through ANVISA, and a market size of USD 316.6 million in 2024, Brazil is the largest clinical trials market in Latin America.
What regulatory changes are affecting Brazil's clinical trials?
New legislation effective August 2024 streamlines trial approvals and strengthens participant protections. ANVISA is also expanding acceptance of real-world evidence, adaptive trial designs, and digital health technologies including remote monitoring and decentralized trial elements.
Primary Sources
- ReBEC (Registro Brasileiro de Ensaios Clínicos) — Official registry data: 18,534 total trials, 9,414 fully registered, 5,123 actively recruiting (Ministry of Health, PAHO, FIOCRUZ)
- ANVISA Authorized Clinical Trials — Brazilian Health Regulatory Agency clinical trial oversight and authorized trial listings
- Fortune Business Insights — Brazil Clinical Trials Market Report: USD 316.6M (2024) to USD 443.5M (2032) at 3.9% CAGR
- Pan American Health Organization (PAHO) — Regional health statistics and clinical research collaboration
- Oswaldo Cruz Foundation (FIOCRUZ) — Brazilian public health research institution and ReBEC co-manager
- IQVIA Inc. — Global CRO active in Brazil clinical trials market
- ICON plc — Clinical research organization with Brazil operations
Related Coverage
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…